Slovakia Pharmaceuticals and Healthcare Report Q1 2010
Business Monitor International, January 2010, Pages: 71
The Slovakia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Slovakia's pharmaceuticals and healthcare industry.
Despite its relatively small drug market, Slovakia remains a key market for major firms in Central and Eastern Europe (CEE). Reinforcing this trend, the country is ranked in seventh position in the publisher’s Business Environment Ratings for Q110 and can be considered a relatively low-risk proposition for multinational pharmaceutical companies.
While Slovakia’s total population size, at 5.4mn, limits absolute spending potential, strong proportions of health funds directed to medicines results in high per-capita spending and good access to higher-priced treatments. Meanwhile an ageing population should continue to bolster top-line figures over the long term. Regulatory-wise, Slovakia’s accession to the European Union (EU) has brought legislation into line with more developed markets, although some concerns prevail. The country also boasts relatively strong Country Risk scores.
In 2009 a new system was launched affecting all new drugs on the market, as well as all drugs already being sold by health insurers. The most recent update, in October 2009, has seen average price reductions of 5% for pharmaceutical products from April 2009. The pricing review covered 65% of marketed products and is estimated to generate savings of EUR95mn (US$143mn) annually. Before April 2010, when the list is next updated, the Ministry of Health aims to reference 90% of marketed products. In addition to negative pressure on prices, there have also been significant revisions to co-payments for pharmaceuticals, largely dependent on ATC classification.
The Slovakian government is considering banning medicine discounts and allowing mail-order pharmacies as part of new legislation which would alter the landscape of the country’s retail pharmaceutical sector. There are between 1,700 and 1,800 registered pharmacies in Slovakia, including 54 state-owned hospital outlets. Medicines used in outpatient care can only be sold in pharmacies, as are non-prescription drugs. Ownership of pharmacies has been an issue of contention for the past 20 years. Around 16% of pharmacies currently belonged to non-pharmaceutical organisations in 2009. Meanwhile 28% of pharmacies are part of a chain, up from 13% in 2004.
The publisher’s Burden of Disease Database (BoDD) shows that Slovakia is among the healthiest countries in the region, with 15,302 disability-adjusted life years (DALYs) lost to all diseases and injuries in 2008. This can be attributed to relatively advanced healthcare standards and the country’s strong devotion to medical and pharmaceutical spending. Through to 2030, widespread improvements in care provisions should cause a significant decrease in the number of DALYs lost.
Executive Summary
SWOT Analysis
- Slovakia Pharmaceuticals Industry SWOT
- Slovakia Political SWOT
- Slovakia Economic SWOT
- Slovakia Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Regional Pharmaceutical Business Environment Ratings Q110
- Limits Of Potential Returns
- Risks To Realisation Of Returns
Slovakia – Market Summary
Regulatory Regime
Generic Drug Legislation
- Intellectual Property Regime
- IP Deficiencies
- Pricing Regime
- Reimbursement Regime
- Pricing Developments
- Eurozone Entry
- Table: Slovakia – Exchange Rates, 2005-2013
Industry Trends And Developments
- Epidemiology
- Table: Main Causes Of Mortality And Morbidity In Slovakia, 2006
- Table: Disease Burden In CEE
- Healthcare Sector
- Healthcare Sector Reforms
- Health Insurance
- Recent Health Insurance Developments
- Healthcare Funding Crisis
- Regional Healthcare Sector Developments
- Research And Development
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors – Industry
- Key Growth Factors – Macroeconomic
- Table: Slovakia – Economic Activity, 2007-2014
- Prescription Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Export/Import Forecasts
- Medical Device Market Forecast
- Table: EU Medical Device Classifications
- Other Healthcare Data Forecasts
- Key Risks To BMI’s Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Recent Pharmaceutical Industry Developments
- Distribution Sector
Company Monitor
- Multinational Company Profiles
- GlaxoSmithKline (GSK)
- Sanofi-Aventis
- Pfizer
- Indigenous Company Profiles
- Zentiva (now merged with Sanofi-Aventis and incorporating Sicomed)
- Biotika
- Hoechst-Biotika (to be renamed HBM Pharma Ltd)
- Imuna Pharma
Country Snapshot: Slovakia Demographic Data
- Section 1: Population:
- Table: Demographic Indicators
- Table: Rural/Urban Breakdown
- Section 2: Education & Healthcare
- Table: Education
- Table: Healthcare: Vital Statistics
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators
- Table: Consumption And Stratification
- Table: Wages Per Year
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Data Tables
- GlaxoSmithKline (GSK)
- Sanofi-Aventis
- Pfizer
- Zentiva (now merged with Sanofi-Aventis and incorporating Sicomed)
- Biotika
- Hoechst-Biotika (to be renamed HBM Pharma Ltd)
- Imuna Pharma
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
